Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ANTH's Cash to Debt is ranked higher than
78% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. ANTH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANTH' s 10-Year Cash to Debt Range
Min: 0.29  Med: 3.59 Max: No Debt
Current: No Debt
Equity to Asset 0.73
ANTH's Equity to Asset is ranked higher than
55% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANTH: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ANTH' s 10-Year Equity to Asset Range
Min: 0.73  Med: 0.77 Max: 0.81
Current: 0.73
0.73
0.81
F-Score: 5
Z-Score: 2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -5709.36
ANTH's Operating margin (%) is ranked lower than
89% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. ANTH: -5709.36 )
Ranked among companies with meaningful Operating margin (%) only.
ANTH' s 10-Year Operating margin (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -5709.36
Net-margin (%) -5802.81
ANTH's Net-margin (%) is ranked lower than
89% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. ANTH: -5802.81 )
Ranked among companies with meaningful Net-margin (%) only.
ANTH' s 10-Year Net-margin (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -5802.81
ROE (%) -207.48
ANTH's ROE (%) is ranked lower than
90% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ANTH: -207.48 )
Ranked among companies with meaningful ROE (%) only.
ANTH' s 10-Year ROE (%) Range
Min: -582.71  Med: -473.78 Max: -179.7
Current: -207.48
-582.71
-179.7
ROA (%) -123.91
ANTH's ROA (%) is ranked lower than
87% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. ANTH: -123.91 )
Ranked among companies with meaningful ROA (%) only.
ANTH' s 10-Year ROA (%) Range
Min: -254.43  Med: -141.49 Max: -94.5
Current: -123.91
-254.43
-94.5
ROC (Joel Greenblatt) (%) -6223.42
ANTH's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. ANTH: -6223.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -263793.33  Med: -14312.76 Max: -2880.94
Current: -6223.42
-263793.33
-2880.94
EBITDA Growth (3Y)(%) -59.60
ANTH's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ANTH: -59.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -59.60 Max: -52
Current: -59.6
EPS Growth (3Y)(%) -59.40
ANTH's EPS Growth (3Y)(%) is ranked lower than
95% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ANTH: -59.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANTH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -59.40 Max: -50.7
Current: -59.4
» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ANTH Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
Jim Simons 26,700 sh (-78.62%)
» More
Q4 2014

ANTH Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

ANTH Guru Trades in Q1 2015

Jim Simons 18,303 sh (New)
» More
Q2 2015

ANTH Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.56
ANTH's P/B is ranked lower than
82% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ANTH: 10.56 )
Ranked among companies with meaningful P/B only.
ANTH' s 10-Year P/B Range
Min: 4.32  Med: 8.30 Max: 16.04
Current: 10.56
4.32
16.04
P/S 366.74
ANTH's P/S is ranked lower than
95% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. ANTH: 366.74 )
Ranked among companies with meaningful P/S only.
ANTH' s 10-Year P/S Range
Min: 341.5  Med: 449.50 Max: 612
Current: 366.74
341.5
612
Current Ratio 4.14
ANTH's Current Ratio is ranked higher than
50% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. ANTH: 4.14 )
Ranked among companies with meaningful Current Ratio only.
ANTH' s 10-Year Current Ratio Range
Min: 0.15  Med: 3.08 Max: 16.1
Current: 4.14
0.15
16.1
Quick Ratio 4.14
ANTH's Quick Ratio is ranked higher than
52% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ANTH: 4.14 )
Ranked among companies with meaningful Quick Ratio only.
ANTH' s 10-Year Quick Ratio Range
Min: 0.15  Med: 3.08 Max: 16.1
Current: 4.14
0.15
16.1
Days Sales Outstanding 376.62
ANTH's Days Sales Outstanding is ranked lower than
95% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ANTH: 376.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANTH' s 10-Year Days Sales Outstanding Range
Min: 0  Med: 0.00 Max: 0
Current: 376.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.64
ANTH's Price/Net Cash is ranked lower than
64% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ANTH: 10.64 )
Ranked among companies with meaningful Price/Net Cash only.
ANTH' s 10-Year Price/Net Cash Range
Min: 2.01  Med: 5.42 Max: 41.88
Current: 10.64
2.01
41.88
Price/Net Current Asset Value 10.16
ANTH's Price/Net Current Asset Value is ranked lower than
65% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. ANTH: 10.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANTH' s 10-Year Price/Net Current Asset Value Range
Min: 1.96  Med: 5.22 Max: 30.45
Current: 10.16
1.96
30.45
Price/Tangible Book 10.01
ANTH's Price/Tangible Book is ranked lower than
76% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. ANTH: 10.01 )
Ranked among companies with meaningful Price/Tangible Book only.
ANTH' s 10-Year Price/Tangible Book Range
Min: 1.96  Med: 4.33 Max: 14.46
Current: 10.01
1.96
14.46
Price/Median PS Value 0.76
ANTH's Price/Median PS Value is ranked higher than
66% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. ANTH: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
ANTH' s 10-Year Price/Median PS Value Range
Min: 0.95  Med: 0.97 Max: 0.98
Current: 0.76
0.95
0.98
Earnings Yield (Greenblatt) (%) -12.22
ANTH's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. ANTH: -12.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANTH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -112.9  Med: 0.00 Max: 0
Current: -12.22
-112.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals Inc was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for ANTH

Headlines

Articles On GuruFocus.com
comment on ANTH Mar 02 2013 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 12 2010 
Weekly CFO Buys Highlight: Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmace Sep 26 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 12 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
The NASDAQ Biotech Index Is Partying Like It's 1999 - Some Say The Party's Just Getting Started,... Aug 24 2015
ANTHERA PHARMACEUTICALS INC Financials Aug 21 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 17 2015
10-Q for Anthera Pharmaceuticals, Inc. Aug 12 2015
Anthera reports 2Q loss Aug 10 2015
Anthera reports 2Q loss Aug 10 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
Anthera Pharmaceuticals Reports 2015 Second Quarter and Operational Update Aug 10 2015
Q2 2015 Anthera Pharmaceuticals Inc Earnings Release - After Market Close Aug 10 2015
Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update on August 10 Jul 30 2015
Should You Sell Anthera Pharmaceuticals (ANTH) Before Earnings? - Tale of the Tape Jul 24 2015
Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13% - Tale of the Tape Jul 21 2015
Anthera Pharmaceuticals Announces Exercise in Full of Underwriters' Option to Purchase Additional... Jul 14 2015
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full... Jul 14 2015
A Chinese Financial Implosion Might Spur Opportunities - Here Are 4 Stocks to Watch Jul 14 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jul 13 2015
Should You Buy Anthera Pharmaceuticals Inc (ANTH) Following Public Offering Of Common Shares? Jul 09 2015
Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering Jul 09 2015
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Jul 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK